Vanda Pharmaceuticals stock (US92178N1054): Short interest rises 10.7% in April

Vanda Pharmaceuticals (VNDA) saw short interest climb to 11.31% of float as of April 30, 2026, up 10.7% from prior month amid Nasdaq trading.

Vanda Pharmaceuticals short interest increased 10.7% in April 2026, reaching 6.20 million shares or 11.31% of the public float as of April 30, according to MarketBeat as of May 2026. The Nasdaq-listed biotech stock closed at $6.42 on recent trading, up 2.39%, with extended hours at $6.50.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Vanda Pharmaceuticals
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe
• Key revenue drivers: HETLIOZ, Fanapt
• Home exchange/listing venue: Nasdaq (VNDA)
• Trading currency: USD

Vanda Pharmaceuticals: core business model

Vanda Pharmaceuticals develops and commercializes innovative therapies for unmet medical needs, focusing on central nervous system disorders and circadian rhythm conditions. The company markets HETLIOZ for non-24-hour sleep-wake disorder and Fanapt for schizophrenia, generating revenue primarily from US sales with growing European presence. Its pipeline includes tradipitant for gastroparesis and other rare diseases.

Main revenue and product drivers for Vanda Pharmaceuticals

HETLIOZ drove significant revenue in recent quarters, with Q1 2026 sales reported at part of $52.59 million total revenue, missing estimates of $54.77 million per TradingView data as of May 2026. Net loss narrowed to $27.21 million from $29.49 million year-over-year. Fanapt contributes steadily, supporting Nasdaq-listed VNDA's position in US biotech markets.

Industry trends and competitive position

The biotech sector faces volatility from clinical trial outcomes and regulatory decisions, with Vanda competing in niche CNS markets. Short interest at 11.31% reflects investor skepticism amid earnings misses, yet recent price gains of 2.39% signal short-term optimism. VNDA's focus on rare diseases provides US investors exposure to high-upside orphan drug approvals.

Why Vanda Pharmaceuticals matters for US investors

Listed on Nasdaq, Vanda offers US retail investors direct access to biotech innovation without international trading hurdles. Its products address US-prevalent conditions like sleep disorders, tying into broader healthcare spending trends in the world's largest pharma market.

Conclusion

Vanda Pharmaceuticals shows mixed signals with rising short interest to 11.31% of float in April 2026 and recent Q1 revenue shortfalls, offset by narrowing losses and price upticks. Investors track pipeline progress and market expansion for potential catalysts. The stock remains a volatile biotech play on Nasdaq.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.